Ropivacaine

Breastfeeding
  • TRADE NAME: Naropin (AstraZeneca)
  • INDICATIONS: Surgical anesthesia, acute pain management
  • CLASS: Anesthetic; local
  • HALF-LIFE: 1.1–2.5 hours after intravascular administration; 3.2–5.2 hours after epidural administration
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Adenosine, Aminophylline, Amiodarone, Ciprofloxacin, Dronedarone, Fluvoxamine, Imipramine, Ketoconazole

PREGNANCY CATEGORY: B

Our database has 34 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
NEUROMUSCULAR/SKELETAL.
OTIC.
OTHER.


Page last updated 07/31/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top